InfuSystem Holdings Inc

InfuSystem Holdings Inc(INFU)の株式分析

$13.150

+0.359 (+2.73%)終値時点

Loading chart…
高値
13.590
始値
13.140
出来高加重平均価格
13.21
出来高
134.96K
時価総額
145.87M
安値
12.895
売買代金
1.78M
EV/EBITDA(TTM)
9.35

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

ir.infusystem.com

AI分析 of InfuSystem Holdings Inc (INFU)

買い

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

バリュエーション指標

InfuSystem Holdings Inc(INFU)の現在の予想PERは22.73で、5年平均は68.23です。

予想PER

適正
5年平均 P/E
68.23
現在のP/E
22.73
割高
139.38
割安
-2.92

予想EV/EBITDA

適正
5年平均 EV/EBITDA
8.84
現在のEV/EBITDA
9.35
割高
11.12
割安
6.56

予想PSR

適正
5年平均 P/S
1.43
現在のP/S
1.70
割高
1.88
割安
0.98

Alphio AI による INFU の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%INFU

$7.68

シナリオ価格

基

基本

基本 · 50%INFU

$6.54

シナリオ価格

弱

弱気

弱気 · 25%INFU

$6.33

シナリオ価格

イベントタイムライン

2026-08-04 (ET)

07:00:00

Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s

07:00:00

Company Reports Q2 Revenue of $36.9M

2026-05-18 (ET)

16:40:00

InfuSystem Approves $20M Stock Repurchase Program

2026-05-07 (ET)

07:30:00

Q1 Revenue at $33.7M, Below Consensus

2026-03-02 (ET)

09:40:00

InfuSystem Trading Resumes

ニュース

INFU のよくある質問 — Alphio AI が回答

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InfuSystem Holdings Inc is a good buy right now, with a current price of $13.84 and a forward P/E ratio of 22.73, indicating reasonable valuation relative to future earnings. The company has shown a robust year-to-date change of +64.96% and a solid gross margin of 57.50% in Q2 2026, reflecting strong operational efficiency. The main risk is the high insider selling activity, which has increased by 1158.53% over the last quarter, suggesting potential concerns among hedge funds.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める